

## MENINGOCOCCAL VACCINATIONS CARD

**This card is intended for the pharmacist or healthcare provider to fill out.**

**Please keep it so you can:**

- See which meningococcal vaccines you have received
- Understand which vaccines you may still need
- Show your vaccination progress to your doctor

**Print this card and bring it with you to every  
vaccination or medical visit.**

---

FIRST NAME

MIDDLE  
INITIAL

LAST NAME

---

DATE OF BIRTH

**When fully completed, keep this card for your records and ask your treating provider or call 1.888.747.4747 to obtain a new card.**

## 2022 ACIP RECOMMENDATIONS FOR MENINGOCOCCAL VACCINATIONS AT LEAST 2 WEEKS PRIOR TO INITIATING A COMPLEMENT INHIBITOR

### MenACWY\*

For **primary series**, administer 2 doses at least 8 weeks apart.  
For **booster vaccination**, administer a single booster dose every 5 years if risk remains.

MenACWY VACCINE MenQuadfi OR Menveo	FIRST DOSE	SECOND DOSE	BOOSTER DOSE	BOOSTER DOSE
VACCINE BRAND				
DATE				
VACCINATION SITE				

**A note to the patient about timing (vaccination provider to fill out):** Since you received your first vaccine on \_\_\_\_\_ (date), you must **RETURN** for another dose on or after \_\_\_\_\_ (date).

### MenB†

For **primary series in patients 10 years or older**,<sup>‡</sup> administer 2 doses of Bexsero at least 1 month apart OR 3 doses of Trumenba at 0, 1 to 2, and 6 months.

For **booster vaccination in patients 10 years or older**,<sup>‡</sup> administer a single booster dose 1 year following completion of the primary series and then every 2 to 3 years if risk remains.

*MenB vaccines are not interchangeable; patient must receive the same product for all doses.*

MenB VACCINE Bexsero OR Trumenba	FIRST DOSE	SECOND DOSE	THIRD DOSE <sup>a</sup> (if Trumenba)	BOOSTER DOSE	BOOSTER DOSE
VACCINE BRAND					
DATE					
VACCINATION SITE					

**A note to the patient about timing (vaccination provider to fill out):** Since you received your first vaccine on \_\_\_\_\_ (date), you must **RETURN** for a second dose on or after \_\_\_\_\_ (date). If you received Trumenba, you must **RETURN** for your final dose on \_\_\_\_\_ (date).

<sup>‡</sup>For Trumenba, if dose 2 was administered at least 6 months after dose 1, then dose 3 is not needed.

\*Two quadrivalent meningococcal conjugate (MenACWY) vaccines are currently licensed in the United States:

1. MenQuadfi® (meningococcal [groups A, C, W, Y] conjugate vaccine [MenACWY-TT])
2. Menveo® (meningococcal groups A, C, W, and Y oligosaccharide diphtheria CRM197 conjugate vaccine [MenACWY-CRM])

†Two serogroup B meningococcal (MenB) vaccines are currently licensed in the United States:

1. Bexsero® (MenB-4C)
2. Trumenba® (MenB-FHbp)

‡For information on the vaccine schedule for children who are 10 years old or younger, please contact the treating physician. Healthcare providers can also call 1.888.765.4747 and ask for Alexion Medical Information for questions related to meningococcal vaccinations for this age group.

To learn more about the latest recommendations regarding meningococcal vaccinations for patients prescribed complement inhibitors, see the Advisory Committee on Immunization Practices (ACIP) recommendations at: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html>.

Vaccinations are required for patients prescribed a complement inhibitor. Vaccinations must be administered at least 2 weeks prior to starting a complement inhibitor due to the risk of life-threatening and fatal meningococcal infections. **Follow the most up-to-date ACIP recommendations for vaccination schedule, revaccinations, and boosters for as long as the patient remains at risk of infection.**

For **comprehensive vaccination support**, reach out to OneSource™—a complimentary patient support program offered by Alexion and designed to support your specific needs:

Call **1.888.765.4747** Visit [www.AlexionOneSource.com](http://www.AlexionOneSource.com) Email [OneSource@alexion.com](mailto:OneSource@alexion.com)

**Reference:** Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep.* 2020;69(9):1-41.

**This material is intended for residents of the United States.**

ALEXION and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc., and OneSource is a trademark of Alexion Pharmaceuticals, Inc.

© 2023, Alexion Pharmaceuticals, Inc. All rights reserved. US/ALL/0649 01/23